Insulet Corp Files 8-K on Director Changes and Compensation

Ticker: PODD · Form: 8-K · Filed: 2024-03-01T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

TL;DR

Insulet's 8-K: New directors elected, exec comp plans updated.

AI Summary

On February 26, 2024, Insulet Corporation filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes the election of new directors and updates to the compensatory plans for its officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine corporate governance matters such as director elections and compensation adjustments, which typically carry low immediate risk.

Key Numbers

Key Players & Entities

FAQ

What specific changes were made to Insulet Corporation's board of directors?

The filing indicates the election of new directors, though specific names are not detailed in the provided excerpt.

What type of compensatory arrangements were updated?

The filing mentions updates to the compensatory arrangements of certain officers, but the specific details of these arrangements are not provided in the excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on February 26, 2024.

What is Insulet Corporation's principal executive office address?

The principal executive offices are located at 100 Nagog Park, Acton, Massachusetts 01720.

What is the SIC code for Insulet Corporation?

The Standard Industrial Classification code for Insulet Corporation is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.

From the Filing

0001145197-24-000013.txt : 20240301 0001145197-24-000013.hdr.sgml : 20240301 20240301160351 ACCESSION NUMBER: 0001145197-24-000013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240226 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 24709495 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 8-K 1 podd-20240226.htm 8-K podd-20240226 0001145197 FALSE 0001145197 2024-02-26 2024-02-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):  February 26, 2024   INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 100 Nagog Park Acton Massachusetts 01720 (Address of Principal Executive Offices, including Zip Code) Registrant’s telephone number, including area code: (978) 600-7000 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value Per Share PODD The NASDAQ Stock Market, LLC Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Compensatory Arrangements of Certain Officers Approval of revised forms of Equity Agreements. On February 26, 2024, the Talent and Compensation Committee (the “Committee”) of the Board of Directors of Insulet Corporation (the "Company") approved revisions to the Company’s forms of Non-Qualified Stock Option Agreement (the “Stock Option Agreement), Restricted Stock Unit Agreement (the “RSU Agreement) and Performance Stock Unit Agreement (the “PSU Agreement) for fiscal 2024 (the Stock Option Agreement, the RSU Agreement, and PSU

View on Read The Filing